肿瘤吸收剂量、代谢反应和乳腺癌肝转移患者放射栓塞后的生存。

IF 2.6 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Osman Melih Topcuoğlu, Türkay Toklu, Nalan Alan Selçuk, Betül Uzunoğlu
{"title":"肿瘤吸收剂量、代谢反应和乳腺癌肝转移患者放射栓塞后的生存。","authors":"Osman Melih Topcuoğlu, Türkay Toklu, Nalan Alan Selçuk, Betül Uzunoğlu","doi":"10.1016/j.jvir.2025.08.045","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (<sup>90</sup>Y) transarterial radioembolization (TARE).</p><p><strong>Materials and methods: </strong>Between August 2016 and August 2024, patients with BCLM who underwent <sup>90</sup>Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression-free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.</p><p><strong>Results: </strong>Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3-9.0 months) and 4.2 months (IQR, 2.5-5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (P = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5-14.8 months) and 4.1 months (IQR, 3.1-6.3 months) versus 4.0 months (IQR, 2.5-4.5 months) and 2.1 months (IQR, 1.3-2.7 months), respectively (P = .025 and P = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (P = .024 and P = .397, respectively).</p><p><strong>Conclusions: </strong>Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases.\",\"authors\":\"Osman Melih Topcuoğlu, Türkay Toklu, Nalan Alan Selçuk, Betül Uzunoğlu\",\"doi\":\"10.1016/j.jvir.2025.08.045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (<sup>90</sup>Y) transarterial radioembolization (TARE).</p><p><strong>Materials and methods: </strong>Between August 2016 and August 2024, patients with BCLM who underwent <sup>90</sup>Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression-free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.</p><p><strong>Results: </strong>Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3-9.0 months) and 4.2 months (IQR, 2.5-5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (P = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5-14.8 months) and 4.1 months (IQR, 3.1-6.3 months) versus 4.0 months (IQR, 2.5-4.5 months) and 2.1 months (IQR, 1.3-2.7 months), respectively (P = .025 and P = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (P = .024 and P = .397, respectively).</p><p><strong>Conclusions: </strong>Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.</p>\",\"PeriodicalId\":49962,\"journal\":{\"name\":\"Journal of Vascular and Interventional Radiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Vascular and Interventional Radiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jvir.2025.08.045\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vascular and Interventional Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jvir.2025.08.045","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨经动脉放射栓塞(TARE)治疗乳腺癌肝转移(BCLM)患者肿瘤吸收剂量(TAD)与肿瘤反应及生存期的关系。方法与材料:回顾性分析2016年8月至2024年8月间行玻璃颗粒Y90-TARE治疗的BCLM患者。主要结局是总生存期(OS)和肝脏无进展生存期(hPFS)。次要终点为客观有效率。使用实体瘤正电子发射断层扫描反应标准(PERCIST)评估对治疗的反应。患者分为有反应组和无反应组。结果或发现:42例女性中有26例患者符合纳入标准,平均年龄为57.9±13.8岁。所有患者的中位OS和hPFS分别为6.1个月(IQR; 4.3-9.0个月)和4.2个月(IQR; 2.5-5.6个月)。应答者和无应答者的中位TAD分别为157 Gy和150 Gy (p=0.768)。应答者与无应答者的中位OS和hPFS分别为8.3个月(IQR; 5.5-14.8个月)和4.1个月(IQR; 3.1-6.3个月),而4.0个月(IQR; 2.5-4.5个月)和2.1个月(IQR; 1.3-2.7个月),分别为(p= 0.025和p= 0.210)。在145 Gy以上,TAD表现出显著的OS获益,但没有改变肝脏hPFS (p = 0.024和p = 0.397)。结论:在本研究中,影像学反应与OS有一定相关性,而TAD与反应无相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases.

Purpose: To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (90Y) transarterial radioembolization (TARE).

Materials and methods: Between August 2016 and August 2024, patients with BCLM who underwent 90Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression-free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.

Results: Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3-9.0 months) and 4.2 months (IQR, 2.5-5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (P = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5-14.8 months) and 4.1 months (IQR, 3.1-6.3 months) versus 4.0 months (IQR, 2.5-4.5 months) and 2.1 months (IQR, 1.3-2.7 months), respectively (P = .025 and P = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (P = .024 and P = .397, respectively).

Conclusions: Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
10.30%
发文量
942
审稿时长
90 days
期刊介绍: JVIR, published continuously since 1990, is an international, monthly peer-reviewed interventional radiology journal. As the official journal of the Society of Interventional Radiology, JVIR is the peer-reviewed journal of choice for interventional radiologists, radiologists, cardiologists, vascular surgeons, neurosurgeons, and other clinicians who seek current and reliable information on every aspect of vascular and interventional radiology. Each issue of JVIR covers critical and cutting-edge medical minimally invasive, clinical, basic research, radiological, pathological, and socioeconomic issues of importance to the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信